Exhibit
10.85


 


BioRestorative
Therapies, Inc.


40
Marcus Drive, Suite One


Melville,
New York 11747


 


March
1, 2017


 


Mr.
Robert Paccasassi


27
Ridge Road


Southampton,
New York 11968


 


Dear
Mr. Paccasassi:


 


Reference
is made to the Executive Employment Agreement, dated as of September 2, 2015, between BioRestorative Therapies, Inc. (the “Company”)
and you (the “Executive”) as amended (the “Employment Agreement”). All capitalized terms used and not
defined herein shall have the meanings ascribed to them in the Employment Agreement.


 


Pursuant
to the Employment Agreement, the Executive is entitled to receive an annual bonus of up to 25% of his Per Annum Salary based upon
the satisfaction of certain performance goals. The parties agree that, for the year ended December 31, 2016, the Executive instead
is entitled to receive an annual bonus of up to 20% of his Per Annum Salary based upon the satisfaction of the revised performance
goals set forth on Schedule A attached hereto. The Company acknowledges and agrees that, as of the date hereof, the initial two
(2) performance goals set forth on Schedule A have been satisfied.


 


The
parties agree further that the performance goals for the year ending December 31, 2017, and the bonus amount payable with respect
thereto, are as set forth on Schedule B attached hereto.


 


Except
as amended hereby, the Employment Agreement shall continue in full force and effect in accordance with its terms.


 


	 	Very truly yours,
	 	 
	 	BioRestorative Therapies, Inc. 
	 	 	 
	 	By:
    	                          
	 	 	Mark
    Weinreb, Chief Executive Officer


 


Agreed:


 


	 	 
	Robert
    Paccasassi	 


 




    	 	 	 



    	 



    

 


SCHEDULE
A


 


2016
Bonus Milestones:


 


	 	●	$17,500
    in the event the Company files an IND application with regard to the commencement of a clinical trial for the Company’s
    BRTX-100 product (the “Clinical Trial”) (the “IND Application”) with the Food and Drug Administration
    (the “FDA”);
	 	 	 
	 	●	$8,750
    in the event the FDA clears the IND Application;
	 	 	 
	 	●	$8,750
    upon testing and receipt of certification that the Company’s fully equipped cleanroom has attained an ISO Class 7 cleanliness
    level.


 


It
is understood and agreed that (i) the filing of the IND Application with the FDA had to be achieved by December 31, 2016 in order
for the Executive to be entitled to receive the Bonus amount; and (ii) the other milestones may occur by July 31, 2017. In addition,
the Executive must have remained continuously employed with the Company through the date on which a particular milestone is satisfied
in order for the Executive to be entitled to receive the particular Bonus amount. Any issue as to whether any of the foregoing
milestones have been satisfied shall be determined by the Company in its sole discretion.


 




    	 	 	 



    	 



    

 


SCHEDULE
B


 


2017
Bonus Milestones:


 


	 	●	$10,938
    in the event the Company completes the set up and qualification of its clean process areas in connection with the Clinical
    Trial and obtains all necessary equipment and staffing with respect thereto;
	 	 	 
	 	●	$10,937
    in the event the Company identifies and qualifies external or internal quality control laboratory operations supporting raw
    material, environmental monitoring and final product release testing;
	 	 	 
	 	●	$13,125
    in the event a patient in the Clinical Trial receives a dose of BRTX-100;
	 	 	 
	 	●	$8,750
    in the event the Company’s management approves the 2017 GMP audit plan (the “Plan”) and one audit contemplated
    in the Plan is completed.


 


It
is understood and agreed that each of the foregoing milestones must be achieved by December 31, 2017 in order for the Executive
to be entitled to receive the Bonus amount. In addition, the Executive must have remained continuously employed with the Company
through the date on which a particular milestone is satisfied in order for the Executive to be entitled to receive the particular
Bonus amount. Any issue as to whether any of the foregoing milestones have been satisfied shall be determined by the Company in
its sole discretion.